

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### The effect of selenium administration on complete blood count in elderly patients admitted to critical care unit

#### Protocol summary

##### Study aim

Determining the effect of selenium administration on complete blood count (CBC) in the elderly admitted to the intensive care unit

##### Design

A double-blind randomized clinical trial with two groups: Selenium and control group

##### Settings and conduct

The study will be conducted at Imam Reza and Shohada Hospital. Patients will be randomly divided into two groups of selenium, and Selin by the block method. The researchers and participants will not be aware of the groups involved.

##### Participants/Inclusion and exclusion criteria

Patients over 60 years admitted to the intensive care unit of Shohada and Imam Reza Hospital with an APACHE II score above 15 will be included in the study. Exclusion criteria include a history of malignancy, Renal failure, and Suppression of the immune system

##### Intervention groups

Selenium group will receive bolus administration of selenium (3000 µg) for 3 hours in the beginning, and then they will receive 1500 µg /day for one hour for 10 days. Patients in the control group will receive normal saline for 10 days.

##### Main outcome variables

Platelet amount that will be checked with complete blood count.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20091012002582N23**

Registration date: **2021-05-18, 1400/02/28**

Registration timing: **prospective**

Last update: **2021-05-18, 1400/02/28**

Update count: **0**

##### Registration date

2021-05-18, 1400/02/28

##### Registrant information

###### Name

Ata Mahmoodpoor

###### Name of organization / entity

Tabriz University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 914 116 0888

###### Email address

mahmoodpoora@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-05-22, 1400/03/01

##### Expected recruitment end date

2022-06-05, 1401/03/15

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of selenium administration on complete blood count in elderly patients admitted to critical care unit

##### Public title

The effect of selenium administration on complete blood count in elderly patients admitted to critical care unit

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

**Inclusion criteria:**

patients above 60 years admitted to critical care unit  
APACHE II above 15

**Exclusion criteria:**

History of malignancy Renal failure Suppression of the immune system

**Age**

From **60 years** old to **100 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Investigator

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Initially, the blocks (n=4) with different arrangements of A and B will be defined. Considering the different probable arrangements of A and B, blocks will be numbered from 1 to 6. To enroll the initial 4 patients into the study, one of the arrangements will be selected using the random digit table and the patients will be assigned into the A and B groups accordingly. For the next 4 patients, the arrangement pattern will be selected again and the patients will be assigned to the groups and this cycle will be repeated to achieve our intended sample size. The unpredictability of assignment and balancing the number of patients across the two groups during or at the end of the study are the main advantages of this method. Notably, the patients will be assigned into the study based on the ICU date of admission and nobody will be able to assign the patients to the specific group of interest.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

The aim of double-blinding is the avoidance of patients and researchers from being informed about the study intervention, so enrollment of patients in groups will not be recognized. The patients will be assigned into the study based on the ICU date of admission and determined series by randomization process ( based on blocks) and the researcher will not be aware of the patient's assignment in the intervention and control groups. The informed consent will be obtained from the patient's next of kin and they will thoroughly be informed about the study but they will be blind about the group in which their patient will be included.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Tabriz University of Medical Sciences

**Street address**

Golgasht street, Tabriz, Iran

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Approval date**

2021-02-22, 1399/12/04

**Ethics committee reference number**

IR.TBZMED.REC.1399.1076

**Health conditions studied****1****Description of health condition studied**

Other infectious disease

**ICD-10 code**

B99.8

**ICD-10 code description**

Other infectious disease

**Primary outcomes****1****Description**

platelet

**Timepoint**

days 1th and 10th

**Method of measurement**

Complete blood count

**Secondary outcomes****1****Description**

Red Cell Distribution Width

**Timepoint**

Days 1th and 10th

**Method of measurement**

Complete blood count

**2****Description**

The ratio of neutrophils to lymphocytes

**Timepoint**

Days 1th and 10th

**Method of measurement**

Complete blood count

**Intervention groups****1****Description**

Intervention group: Patients in the intervention group will receive bolus administration of IV selenium (3000 µg) (produced by Biosyn company, Germany) during 3 hours at the beginning, and then they will receive 1500 µg /day during one hour for 10 days

**Category**

Treatment - Drugs

**2****Description**

Control group: Patients in control group will receive normal saline as the same volume and speed for 10 days.

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Shohada hospital, ICU

**Full name of responsible person**

Ata Mahmoodpoor

**Street address**

ICU, Shohada hospital, El-Goli street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3336 4667

**Email**

research-vice@tbzmed.ac.ir

**2****Recruitment center****Name of recruitment center**

General ICU of Imam Reza hospital

**Full name of responsible person**

Ata Mahmoodpoor

**Street address**

General ICU, Imam Reza hospital, Golgasht street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3336 4667

**Email**

research-vice@tbzmed.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Mohammad Samiei

**Street address**

Golgasht street, Tabriz, Iran

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3334 4280

**Email**

research-vice@tbzmed.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Ata Mahmoodpoor

**Position**

Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Golgasht street, Tabriz, Iran

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3336 4667

**Email**

amahmoodpoor@yahoo.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Ata Mahmoodpoor

**Position**

Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Faculty of Medicine, Golgasht street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3336 4667

**Email**

amahmoodpoor@yahoo.com

**Person responsible for updating data****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Sarvin Sanaie

**Position**

Assistant professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Golgasht street, Tabriz, Iran

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3334 2178

**Email**

sarvin\_so2000@yahoo.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

No more information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available